Bone Biologics 将来の成長

Future 基準チェック /06

Bone Biologics は収益が増加すると予測されています。EPS は、年間増加すると予測されています55%。

主要情報

30.7%

収益成長率

55.0%

EPS成長率

Biotechs 収益成長	28.5%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18

業績と収益の成長予測

NasdaqCM:BBLG - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-4	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
9/30/2024	N/A	-7	-5	-5	N/A
6/30/2024	N/A	-5	-7	-7	N/A
3/31/2024	N/A	-6	-10	-10	N/A
12/31/2023	N/A	-9	-10	-10	N/A
9/30/2023	N/A	-7	-9	-9	N/A
6/30/2023	N/A	-6	-7	-7	N/A
3/31/2023	N/A	-5	-4	-4	N/A
12/31/2022	N/A	-1	-4	-4	N/A
9/30/2022	N/A	-3	-2	-2	N/A
6/30/2022	N/A	-2	-2	-2	N/A
3/31/2022	N/A	-2	-2	-2	N/A
12/31/2021	N/A	-2	-1	-1	N/A
9/30/2021	N/A	-2	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-2	0	0	N/A
12/31/2020	N/A	-2	0	0	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	-1	-1	N/A
3/31/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-4	-4	-4	N/A
6/30/2019	N/A	-4	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-6	-4	-4	N/A
6/30/2018	N/A	-8	N/A	-3	N/A
3/31/2018	N/A	-6	N/A	-3	N/A
12/31/2017	N/A	-7	N/A	-3	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-16	N/A	-5	N/A
3/31/2017	N/A	-22	N/A	-6	N/A
12/31/2016	N/A	-26	N/A	-7	N/A
9/30/2016	N/A	-24	N/A	-7	N/A
6/30/2016	N/A	-23	N/A	-7	N/A
3/31/2016	N/A	-19	N/A	-6	N/A
12/31/2015	N/A	-14	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-4	N/A
6/30/2015	N/A	-6	N/A	-4	N/A
3/31/2015	N/A	-6	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	0	N/A
3/31/2014	N/A	-1	N/A	0	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BBLG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BBLG今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: BBLG今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: BBLGの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: BBLG来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BBLGの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Bone Biologics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased to US$4.88

Price target decreased to US$4.88

Recent updates

New major risk - Financial position

Bone Biologics Corporation Appoints Phillip Meikle to Board of Directors

Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective Immediately

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.

Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024

New major risk - Share price stability

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.

Bone Biologics Corporation has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Bone Biologics Corporation has filed a Follow-on Equity Offering.

Bone Biologics Corporation Announces Board Changes

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation Receives Non-Compliance Notice From Nasdaq

New major risk - Financial position

Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023

New major risk - Share price stability

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price Requirement

Bone Biologics Corporation Resigns Stephen Laneve as Director

Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price Requirement

Price target decreased to US$4.88

Price target decreased to US$4.88

Bone Biologics Corporation has completed a Composite Units Offering.

Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.

Bone Biologics prices $5.1M underwritten public offering

Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Less than half of directors are independent

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘